| 000 | 01769 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516080227.0 | ||
| 264 | 0 | _c20120615 | |
| 008 | 201206s 0 0 eng d | ||
| 022 | _a1555-8576 | ||
| 024 | 7 |
_a10.4161/cbt.13.2.18876 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBarboza, Nora M | |
| 245 | 0 | 0 |
_aPlitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. _h[electronic resource] |
| 260 |
_bCancer biology & therapy _cJan 2012 |
||
| 300 |
_a114-22 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAntigens, CD20 _xgenetics |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBurkitt Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aCell Cycle _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aDepsipeptides _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aPeptides, Cyclic |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aMedina, Daniel J | |
| 700 | 1 | _aBudak-Alpdogan, Tulin | |
| 700 | 1 | _aAracil, Miguel | |
| 700 | 1 | _aJimeno, José M | |
| 700 | 1 | _aBertino, Joseph R | |
| 700 | 1 | _aBanerjee, Debabrata | |
| 773 | 0 |
_tCancer biology & therapy _gvol. 13 _gno. 2 _gp. 114-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4161/cbt.13.2.18876 _zAvailable from publisher's website |
| 999 |
_c21547570 _d21547570 |
||